Czech National Bank Has $37.41 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• The Czech National Bank increased its stake in **Thermo Fisher Scientific Inc.** by 5.0%, now holding shares worth **$37.41 million** after purchasing an additional 4,418 shares in the second quarter.
• Thermo Fisher recently reported earnings of **$5.36 per share**, surpassing expectations, with a **revenue** of **$10.86 billion** for the quarter, reflecting a **2.9% year-over-year** increase.
• The company declared a quarterly dividend of **$0.43 per share**, with an ex-dividend date of **September 15th**, representing an annual yield of **0.4%**.

Czech National Bank boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 92,272 shares of the medical research company's stock after purchasing an additional 4,418 shares during the quarter. Czech National Bank's holdings in Thermo Fisher Scientific were worth $37,413,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $25,000. CBIZ Investment Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares during the period. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $30,000. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $31,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 1.0%

NYSE:TMO opened at $474.73 on Tuesday. The firm's fifty day moving average is $467.98 and its 200-day moving average is $450.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The firm has a market cap of $179.26 billion, a P/E ratio of 27.46, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $490.00 to $550.00 in a report on Thursday, September 11th. Seventeen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.